A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma. by McTiernan, A. et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2006, Article ID 41080, Pages 1–5
DOI 10.1155/SRCM/2006/41080
Clinical Study
A Phase II Nonrandomised Open-Label Study of Liposomal
Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma
Anne McTiernan,1 Jeremy Whelan,1 Michael Leahy,2 Penella J. Woll,3, 4 and Ian Judson5
1 Meyerstein Institute of Oncology, The Middlesex Hospital, University College London Hospitals (UCLH),
London W1T 3AA, UK
2 St James Univesity Hospitals, Leeds Cancer Centre, Leeds LS9 7TF, UK
3 Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham NG5 1PB, UK
4 University of Sheﬃeld, Weston Park Hospital, Sheﬃeld S10 2SJ, UK
5 Sarcoma Unit, Royal Marsden NHS Trust, 203 Fulham Road, London SW3 6JJ, UK
Received 26 April 2005; Revised 30 December 2005; Accepted 14 February 2006
Thirty four patients with advanced soft tissue sarcoma not previously treated with an anthracycline were treated with DaunoXome
100mg/m2 every 3 weeks. Thirty-three patients were evaluable for toxicity. Grade 3-4 neutropenia was seen in 20 patients (60.6%),
complicated by febrile neutropenia in 2 (6.1%). Other grade 3 toxicities were rare. Among 32 patients assessable for response, one
patient had a partial response, giving a response rate of 3.13% (95% confidence interval, 0.08–16.22%). Seven patients (21.9%)
had stable disease, and 24 patients (75.0%) had disease progression. The median time to progression for all patients was 42 days
(95% CI, 39–49) and the progression-free rate at 3 months was 12.5%. In conclusion, DaunoXome at this dose and schedule is
well tolerated in patients with advanced soft tissue sarcoma, but is not associated with significant activity. Further studies at this
dose and schedule cannot be recommended in this disease.
Copyright © 2006 Anne McTiernan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
For patients with advanced or metastatic adult soft tissue sar-
comas, the response rate to anthracycline-containing first-
line chemotherapy regimens is 26%, and the median sur-
vival is just 12 months [1]. Hence there is need for more
eﬀective treatments in this group of patients. Doxorubicin
appears to be the most active agent in advanced soft tis-
sue sarcoma, with a meta-analysis of 764 patients treated
with single-agent doxorubicin finding a response rate be-
tween 16% and 27% [2]. However, treatment with doxoru-
bicin is limited by mucositis, bone marrow suppression, and
cardiotoxicity. Alternative anthracyclines have eﬃcacy in soft
tissue sarcoma, but none has proved superior to doxorubicin
[3, 4]. There is as yet no compelling evidence that combi-
nation chemotherapy regimens are superior to single-agent
doxorubicin [5].
Liposomal anthracyclines may oﬀer an advantage over
conventional anthracycline preparations, as they have been
shown selectively to enhance the delivery of drug to tumours
whilst reducing the toxicity profile [6–8]. DaunoXome is a
liposomal formulation of daunorubicin in which the drug is
entrapped into small unilamellar vesicles (40–60 nm) com-
posed of a 2 : 1molar ratio of highly purified distearoyl phos-
phatidylcholine and cholesterol. In human pharmacokinetic
studies, DaunoXome administration resulted in a greater
than 100-fold increase in mean peak plasma levels compared
to conventional drug, with a 36-fold increase in the area un-
der the plasma curve [7]. Initial phase I studies in refrac-
tory solid tumours determined the maximum tolerated dose
to be 100–120mg/m2 every 3 weeks, with the dose-limiting
toxicity being myelosuppression [8]. Severe cardiotoxicity is
rare, with one study finding no cardiac toxicity in 88 patients
treated with a cumulative dose between 600 and 3159mg/m2
[9].
Activity with liposomal daunorubicin has been demon-
strated in a range of tumours including the breast cancer
[10], the childhood brain cancers [11], the non-Hodgkin’s
lymphoma [12], and the most notably in Kaposi’s sarcoma
[13, 14] for which liposomal daunorubicin is now licensed.
The aim of this study was to assess the therapeutic activity
of DaunoXome as first-line treatment in advanced soft tissue
sarcoma of adults. The endpoints of the study were objective
response rate, duration of response, and toxicity.
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PATIENTS AND METHODS
Eligibility criteria
Patients with histologically proven soft tissue sarcoma, and
locally advanced or metastatic disease unsuitable for curative
treatment with surgery or radiotherapy, were included. Pa-
tients had to have bidimensionally measurable disease with
evidence of progression within 6 weeks prior to treatment.
Other eligibility criteria included age ≥ 18 years; World
Health Organization (WHO) performance status≤ 2; life ex-
pectancy of 12 weeks or greater; absolute neutrophil count
of ≥ 2 ×109/L and platelets ≥ 100×109/L; serum creatinine
≤ 140 µmol/L; serum bilirubin ≤ 1.25× upper normal limit
(N); and AST ≤ 2× N (≤ 3× N in the case of liver metas-
tases). Patients who had received prior chemotherapy for
advanced disease were excluded, as were patients who had
received adjuvant anthracycline therapy. A minimum of 4
weeks (8 weeks in the case of extensive prior radiotherapy)
must have elapsed between the end of prior radiotherapy and
entry into the protocol.
Ethics approval was granted at all participating institu-
tions, and written informed consent was obtained from all
patients in accordance with local regulatory guidelines prior
to study entry.
Study evaluations
At study entry, and prior to each course of chemotherapy,
patients had a complete history and physical examination.
Blood tests, including renal, liver, and bone biochemistry
were performed every three weeks, together with a weekly full
blood count. Left ventricular ejection fraction was evaluated
at baseline and after every 2 cycles of chemotherapy. Clini-
cal and/or radiological assessment of disease was performed
within 8 days prior to the first infusion, and after every 2 cy-
cles of chemotherapy thereafter, using the same method of
evaluation.
Treatment
DaunoXome 100mg/m2 was diluted with 5% dextrose injec-
tion and infused intravenously over a minimum of 2 hours,
on an outpatient basis. Cycles were repeated every 21 days,
upon recovery of neutrophils to≥ 2.0×109/L. Treatment was
limited to two cycles except in patients who showed unequiv-
ocal benefit from treatment with DaunoXome. In the ab-
sence of obvious disease progression after one cycle, patients
were reassessed for response after 2 cycles. Patients showing
an objective response, that is, complete or partial remission,
received at least 2 further cycles of treatment, and continued
on DaunoXome until disease progression or clinician or pa-
tient choice. Patients with minor response or disease stabili-
sation were also allowed to continue.
Toxicity was graded according to the National Cancer
Institute–Common Toxicity Criteria (NCI-CTC), version 2.0
[15].
Evaluation of response
Response to DaunoXome was assessed after every two cycles
of chemotherapy according to the WHO criteria for clinical
response [16].
Statistical methods
Prior to the initiation of the study, it was considered that
the lowest limit of therapeutic activity of interest was a re-
sponse rate to DaunoXome of 20%. TheGehan two-step pro-
cedure was used to calculate the number of patients required
[17]. Initially, 14 eligible patients would be recruited. If no
responses were observed in these patients, the study would
be terminated. Under these conditions, the probability of re-
jecting the treatment, if it was at least 20% eﬀective, was less
than 5%. If at least one response was observed, more patients
would be added depending on the number of responses ob-
served in order to estimate the therapeutic eﬀectiveness with
a standard error of 10%.
RESULTS
Between July 1998 and August 2002, 36 patients from 4 cen-
tres were enrolled on the study. Two patients were subse-
quently found to be ineligible due to a diagnosis of gastroin-
testinal leiomyosarcoma in both cases. The patient charac-
teristics for the remaining 34 eligible patients are given in
Table 1.
Treatment
A total of 83 cycles was given, with a median of 2 cycles per
patient (range, 1–6). Two patients required a dose reduction
to 80mg/m2 for second and subsequent cycles of chemother-
apy due to febrile neutropenia after the first cycle of treat-
ment. Treatment was repeated at a median of 21 days (range,
20–28). Only 2 patients experienced treatment-related de-
lays. One patient required a 2-day delay because of febrile
neutropenia in the preceding cycle, and one patient had an
allergic reaction to cycle 2 for which the infusion was discon-
tinued, but was successfully retreated at full dose 7 days later,
with antihistamine and corticosteroid prophylaxis.
Toxicity
Thirty three patients were evaluable for assessment of tox-
icity. One further patient had an allergic reaction after just
10 minutes of treatment, following which the infusion was
terminated and no further drug was given. This patient was
therefore only eligible for assessment of hypersensitivity re-
actions.
There were no deaths attributable to the study drug. The
principal haematological toxicity was leukopenia, with 20 pa-
tients (60.6%) experiencing grade 3-4 neutropenia, compli-
cated by febrile neutropenia in 2 patients (6.1%). Grade 3-4
thrombocytopenia and anaemia were rare, occurring in just 2
patients (6.1%) and 1 patient (3.0%), respectively. The most
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Table 1: Patient characteristics (n = 34).
No (%)
Male : Female 15 : 19
Median age: 59 years (range, 28–80)
WHO performance status
0 6 (17.6)
1 23 (67.6)
2 5 (14.7)
Histological subtype
Leiomyosarcoma 14 (41.2)
Unclassified 6 (17.6)
Liposarcoma 3 (8.8)
Angiosarcoma 2 (5.9)
Synovial sarcoma 2 (5.9)
Malignant fibrous histiocytoma 2 (5.9)
Malignant peripheral nerve sheath tumour 2 (5.9)
Other∗ 3 (8.8)
Primary site
Thigh 8 (23.5)
Buttock 5 (14.7)
Uterus 4 (11.8)
Intra-abdominal 4 (11.8)
Retroperitoneal 2 (5.9)
Knee or lower leg 5 (14.7)
Other† 6 (17.6)
Site of disease at start of treatment
Primary site/recurrence 13 (38.2)
Lung 22 (64.7)
Soft tissue 5 (14.7)
Liver 6 (17.6)
Skin 3 (8.8)
Lymph 3 (8.8)
Bone 2 (5.9)
No of sites of disease
1 20 (58.8)
2 9 (26.5)
≥ 3 5 (14.7)
Prior treatment
Surgery —
Curative 25 (73.5)
Palliative 1 (2.9)
Radiotherapy 13 (38.2)
Chemotherapy 0
Median time from diagnosis to start of DanuoXome 10 months (range, 0–147)
Median time from last radiotherapy administration to start of DaunoXome (n = 13) 8 months (range, 2–39)
∗Clear cell (1), haemangiopericytoma (1), pleiomorphic rhabdomyosarcoma (1).
†Anterior/posterior mediastinal (2), paravertebral (1), shoulder (1), upper arm (1), renal (1).
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frequent nonhaematological toxicity was nausea, occurring
in 24 patients (72.7%), although this was only severe (grade
3) in 4 patients. Other nonhaematological grade 3 toxici-
ties included infection (1 patient); lethargy (2 patients); di-
arrhoea (1 patient); and vomiting (1 patient). Alopecia was
observed in 9 patients, but this was mild in all cases. There
were no reported cases of cardiac toxicity.
Hypersensitivity reactions occurred in 3 of the 34 pa-
tients (8.8%). Two patients experienced moderate reactions,
with facial flushing and back pain. Both patients were treated
with intravenous antihistamine and corticosteroids and were
able to complete the treatment as planned, with a slower rate
of infusion. One further patient with a history of hyperten-
sion and two prior transient ischaemic attacks experienced
chest pain after 10 minutes of the infusion. The infusion
was discontinued and intravenous antihistamine and steroid
were administered. An ECG was performed which was ab-
normal hence the patient was admitted for observation. The
chest pain resolved after 5 hours and subsequent tests showed
no evidence of myocardial infarction. The patient was dis-
charged home 2 days later. No further drug was administered
and the patient was withdrawn from the study. It is not clear
whether or not this episode was related to study drug treat-
ment.
Response
Thirty two patients were evaluable for response to DaunoX-
ome. One patient with a retroperitoneal sarcoma died of a
perforated duodenal ulcer, 19 days after cycle 1. A causal rela-
tionship with the drug was deemed possible, but not proven.
One further patient discontinued treatment after 10 minutes
due to hypersensitivity, and received no further treatment.
Among the 32 eligible patients, one partial response was
observed in the first 14 patients and the trial was expanded.
In total, 36 patients were treated owing to the lack of alter-
native treatments available for some of these patients and the
level of disease stabilisation observed. The observed response
was in a patient with malignant fibrous histiocytoma, giv-
ing a response rate of 3.13% (95% confidence interval (Cl),
0.08–16.22%). The duration of this response was 77 days.
Seven patients (21.9%), all of whom had progressive disease
in the 6 weeks prior to treatment, had disease stabilisation
in response to DaunoXome for a median of 87 days (range,
65–384). The median time to progression for all patients was
42 days (95% Cl, 39–49) and progression-free survival at 3
months was 12.5%.
Subsequent treatment and survival
Eighteen patients received further treatment, 14 with chemo-
therapy, principally with ifosfamide and/or doxorubicin-
based chemotherapy. One patient, with a partial response to
DaunoXome, achieved a further partial response to single-
agent ifosfamide. No other objective responses were observed
to second-line chemotherapy. The median overall survival
from the start of DaunoXome was 197 days (95% Cl, 144–
250).
DISCUSSION
Although doxorubicin would appear to be among the most
active agents in soft tissue sarcoma, single-agent daunoru-
bicin has also been demonstrated to have activity in this dis-
ease. In a review that included clinical trials, single-investi-
gator reports, and the files of the Investigational Drug Branch
of the National Cancer Institute, a response rate of 20% (util-
izing the response criteria of the Southwest Oncology Group)
was found in 54 patients treated with single-agent daunoru-
bicin, at varying doses and schedules [18]. Although these
reports are subject to selection bias, the response rate of 3%
to liposomal daunorubicin observed in this study is therefore
disappointing, given the higher response rates reported with
conventional anthracyclines.
It is possible that our low response rate was due to a neg-
ative patient selection bias, whereby the perceived low toxi-
city profile of DaunoXome may have led to the selection of
patients with more indolent tumours that were less likely to
respond to treatment, or patients with poorer performance
status. In a study which combined liposomal daunorubicin
100mg/m2 with ifosfamide 5 g/m2 given at four-weekly in-
tervals as first-line treatment for advanced soft tissue sar-
coma, Deckert et al found a response rate of 31.4%, with 11
of 35 patients achieving a partial response [19]. The median
progression-free survival in their study was 10 months.
Although some patients experienced disease stabilisation,
the progression-free rate at 3 months was only 12.5%. This
does not equate with activity by the criteria reported by van
Glabbeke et al [20]. In their analysis, active agents against soft
tissue sarcoma gave progression-free rates of 30%–56% at 6
months and a progression-free rate of < 20% at 3 months
indicated lack of activity.
Toxicity of DaunoXome was tolerable. Only 2 patients
experienced febrile neutropenia and other grade 3 toxicities
were rare. Although mucositis was observed in 8 patients
(24%), this was mild to moderate in all cases. There were no
reported cases of cardiotoxicity, although this was unlikely
to be observed, given that the number of cycles administered
ranged from 1 to 6 (median 2), which would not approach
the cardiotoxic dose of the anthracycline.
In conclusion, single-agent DaunoXome at this dose and
schedule does not appear to be active in patients with ad-
vanced soft tissue sarcoma, and cannot be recommended for
further study in this disease.
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